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ABSTRACT 
 
OBJECTIVE:  The objective of this selective evidence based medicine (EBM) review is to 
determine whether or not the addition of piracetam safely and effectively improve behavioral and 
or cognitive functions in schizophrenia. 
STUDY DESIGN:  The selected review from all English language, primary literature sources 
that were published between 1979 and 1999. 
DATA SOURCES:  Three double blind randomized controlled trials (RCT) and one case 
controlled clinical study that compared piracetam to a visually matched placebo was selected and 
found using Medline, PubMed, Ebscohost, and Cochrane databases. 
OUTCOMES MEASURED:  Each of the trials assessed the effect of Piracetam on behavioral 
and or clinical functions of Schizophrenia patients by utilizing the following assessment tools: 
Brief Psychiatric Rating Scale (BPRS), The Behavior Rating Scale, The Wing Symptom Rating, 
and Positive and Negative Syndrome Scale (PANSS). 
RESULTS:  The trials demonstrated that the mean change before treatment with the use of 
piracetam as opposed to the visually matched placebo, as compared to after the treatment was 
large, with all statistically significant P values ≤ 0.05. This demonstrated that there was 
improvement in behavioral and cognitive functions achieved with the treatment of piracetam 
versus placebo.  
CONCLUSION:  Based on the studies, all reported that with the use of piracetam in 
schizophrenia, there showed improvement of some type of behavioral and or cognitive functions 
above baseline. Although the pattern of outcome was similar in all the studies, there requires a 
continued and more updated investigation to be aimed at determining a specific dose of 
piracetam therapy, a specific patient population for which piracetam is most effective and to 
further elaborate its safety profile outside a controlled research setting. 
KEY WORDS:  Piracetam, Nootropic Drugs, Psychosis, Psychiatric, Schizophrenia, Behavioral 
Functions, Cognitive Functions 
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INTRODUCTION 
Schizophrenia is a pervasive, debilitating mental disease characterized by positive 
symptoms of hallucinations, delusions, and thought disorder (also referred to as psychosis), and 
negative symptoms of chronic social dilapidation.1 The exact mechanism of schizophrenia is 
unknown although research continues to suggest that both chemical and physical abnormalities 
such as excess amounts of neurotransmitter dopamine or unusual chemical balance are associated 
with schizophrenia. There are also identifiable risk factors such as increasing parental age, winter 
birth, early development insults, migration, and genetic linkages.2  It is observed in ~6.6% of all 
first-degree relatives and if both parents are affected, the risk of offspring is 40%.3  
On average the incidence of people suffering from schizophrenia annually is 35 per 
100,000 in population and there is a 1% prevalence in the world that a person will manifest the 
condition during their lifetime, thus making it more common than diabetes, Alzheimer’s disease, 
and multiple sclerosis.3   It typically begins in adulthood with the average onset for men between 
18-25 years old and women between 25-35 years old.4 Schizophrenic patients makes up almost 
30% of new admissions to psychiatric institutions and occupy about half the beds in mental 
hospitals.2 There is not an exact number of healthcare admissions each year due to the broad 
category of mental illness, however, there is an estimated 300,000  episodes of acute 
schizophrenia occurring annually in the United States with costs estimating to be over 50 billion 
dollars.5 Therefore, it is crucial that the Physician Assistants or other healthcare providers be able 
to identify the condition and initiate treatment for the patients. 
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Schizophrenia appears to be a heterogeneous collection of many distinct diseases, which 
remain poorly defined but linked by common clinical features. Three major symptom clusters are 
seen in schizophrenia: positive, negative, and cognitive symptoms. Positive symptoms include 
hallucinations and delusions, experiences that are not characteristic of normal mental life. 
Negative symptoms represent deficits in normal functions such as blunted affect, impoverished 
speech, asocial behavior, and diminished motivation. Cognitive symptoms include deficits in 
working memory and cognitive control of behavior that often prove extremely disabling.6 Some 
additional examples of cognitive control of behavior are organizing, problem solving or task 
switching.  Schizophrenia remains a clinical diagnosis made on the basis of the individual's 
psychiatric history and mental status examination, as no laboratory or imaging studies can 
validly diagnose it.7 Physician Assistants in primary care may be one of the first providers to 
encounter schizophrenia patients, so having knowledge and a high clinical suspicion may help 
establish a diagnosis and treatment plan more rapidly. 
The general treatments for schizophrenia are atypical antipsychotics used to block 
receptors in the brain’s dopamine pathways. They are the cornerstone in acute and maintenance 
treatment of schizophrenia. Atypical antipyschotics also known as second generation 
antipyschotics include aripiprazole, olanazapine, quetiapine, risperidone, and ziprasidone.8 The 
atypical antipsychotic treatment options for schizophrenia all play an effective role on patients 
with schizophrenia. However, as with all medications, each option will have a different effect on 
each patient.  Current general atypical antipsychotic drugs are efficacious for negative symptoms 
and cognitive only and generally lack efficacy for positive symptoms.6 For positive symptoms, 
typical antipsychotics such as haloperidol, chlorpromazine, and fluphenazine can be used. 
However, these drugs have two major drawbacks: it is often difficult to find the best dosage level 
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for the individual patient, and a dosage level high enough to control psychotic symptoms 
frequently produces extrapyramidal side effects, or EPS.4 Successful treatment of the disorder, 
therefore, requires attention not only to psychopathological domains such as positive and 
negative symptoms, but also to cognition and functional capacity. Cognitive dysfunction is an 
important treatment goal of piracetam. Piracetam is a nootropic drug that improves one or more 
aspects of mental functions, predominantly cognitive functions such as working memory, 
motivation and attention.8 Piracetam may be used as an oral supplement for the relief of negative 
symptoms of schizophrenia and in improving cognitive functions will also improve behavioral 
functions.  Although treatment with piracetam, used off label, has been shown to improve 
cognitive performance in schizophrenia and in other neuropsychological disorders worldwide, 
there is still lack of published reports evaluating the effects of the addition of piracetam on 
behavioral and cognitive functions in schizophrenia patients in the United States.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not the addition of 
piracetam is safe and effective in improving behavioral and or cognitive functions in adults with 
schizophrenia. 
METHODS  
 To examine the objective question, this research paper focuses on adults (age ≥ 18 years 
old) with a diagnosis of schizophrenia or psychosis.  All studies that were considered in the 
literature search included interventions of piracetam and a visually matched placebo, provided 
that the study had at least one arm including piracetam as an intervention and one without, to 
assess behavioral or cognitive functions.  Types of studies considered were randomized control 
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trials; however, one study that was selected was a case controlled clinical study which includes 
data analysis.  All patients in the selected articles had similar demographics and characteristics 
(Table 1). 
 Articles that were searched were peer reviewed journal published in the English 
language.  A detailed search was performed through various search engines that included: 
Medline, PubMed, Ebscohost and Cochrane databases. Key words used in the search included: 
piracetam, nootropic drugs, schizophrenia, psychosis, psychiatric, behavioral functions, and 
cognitive functions.  Articles were selected based on their relevance and importance of the 
outcome to the patient (Patient Oriented Evidence That Matters, POEMS).  Inclusion criteria for 
the data sources consisted of double-blinded, placebo controlled RCTs that were the latest 
publishing available.  Exclusion criteria consists of articles that included medications other than 
piracetam, did not compare with a placebo medical conditions aside from psychosis or 
schizophrenia, patients under age 18, pregnant, those with a concomitant physical disability, or 
having a language barrier.  Statistics were then reported based on p-values, mean change from 
baseline, ANOVA F-score, relative benefit increase (RBI), absolute benefit increase (ABI), 
number needed to treat (NNT), and the following assessment scores: Brief Psychiatric Rating 
Scale (BPRS), The Behavior Rating Scale, The Wing Symptom Rating, and the Positive and 
Negative Syndrome Scale (PANSS), were used to assess the severity of the psychosis symptoms 
and rates them to guide the practitioner’s route of therapy.   
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Table 1 - Demographics & Characteristics of included studies 
Study Type # 
Pts 
Age   
(yrs) 
Inclusion Criteria Exclusion 
Criteria 
W/D Intervention 
Chouinard 
G., Annable 
L., Ross-
Chouinard 
A., Fontaine 
F. 198310 
    
RCT 
 
60  54-80 diagnosed as 
having 
schizophrenia 
disorder/affective 
schizophrenic 
disorder; must 
satisfy 
psychiatric, 
neurologic and 
medical criteria 
Pts with major 
cerebral 
impairment or 
focal cerebral 
lesion/ Pts with a 
major physical 
illness 
 
1 Piracetam 
800 mg 2 
tablets TID 
 
Dimond S., 
Scammell R., 
Pryce I., 
Huws D., 
Gray C. 
197911 
    
RCT 
 
24 38-63 male and female 
suffering from 
chronic 
schizophrenia; all 
patients were 
inpatient or 
residing in 
residential hostel 
Concomitant 
physical illness, 
language 
difficulties, 
current disturbed 
behavior, or 
outside 
employment 
0 Piracetam 
800 mg 2 
tabs TID 
 
Noorbala A., 
Akhondzadeh 
S., Davari-
Ashtiani R., 
Amini-
Nooshabadi 
H. 199912               
    
RCT 
 
34 18-41 Minimum score 
of 60 on the 
Positive and 
Negative 
Syndrome Scale 
(PANSS) 
Significant 
organic, 
neurological 
disorders or 
serious psychotic 
disorders other 
than 
schizophrenia; 
pregnant or 
lactating women 
and those of 
reproductive age 
without adequate 
contraception 
0 Piracetam 
3200 mg/d 
Kabes J., 
Erban L., 
Hanzlicek L., 
Skondia V. 
197913 
    
Control 
Clinical 
Trial 
14 23-50 Patients suffering 
from a functional 
psychosis 
None stated 0 Piracetam 
2400mg q/d 
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OUTCOMES MEASURED 
 The outcomes measured were based off each of the trials assessing the safety and efficacy 
of piracetam on several aspects of behavioral and cognitive functions.  This included the mean 
change from baseline, dichotomous data, ANOVA, and PANSS.  In the Chouinard and Kabes’ 
study, efficacy was assessed with the Brief Psychiatric Rating Scale at mean change from 
baseline and conclusion that was also convertible into dichotomous data. Similarly, in the 
Noorbala study, efficacy was assessed via the PANSS at baseline and at conclusion looking at 
positive symptoms, negative symptoms and cognitive symptoms which was also further 
converted into analysis of variance with P-value. The Dimond study assessed efficacy utilizing 
the Wing Symptom Rating and the Behavior Rating Scale at baseline and at conclusion, in which 
data was converted into analysis of variance with F-score.   
RESULTS  
 In order to review the studies, the 12th week was chosen as the point of comparison for 
the Chouinard and Dimond studies while the closest measured time period was the 8th week for 
the Noorbala and Kabes studies.  The Chouinard et al study was a double blind RCT that 
consisted of 60 elderly patients ranging from 54-80 years old, although only 20 patients were 
randomly assigned to 12 weeks of treatment with piracetam and the others to placebo.   
Chouinard- specifically shows that with treatment, patients showed improvement in alertness and 
reported no withdrawal after discontinued use of the intervention and returned to their original 
condition within a month.  The Dimond et al study was also a double blind crossover RCT that 
consisted of 24 patients ranging from 38-63 years old that participated in the study and was 
diagnosed with chronic schizophrenia.  Dimond studied piracetam and the general facilitation of 
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performances producing fewer errors on this task which involves registering the tactual 
experience of number and preserving it in memory for recall. The Noorbala et al study, another 
double blind RCT was performed on 34 patients ranging from 18-41 years old and a minimum 
score of 30 on the PANSS was required for entry into the study.  Noorbala studied piracetam 
with haloperidol and placebo with haloperidol and showed significant mean change from 
baseline with regards to PANSS. Finally, the Kabes et al study was a controlled clinical study 
with 14 participants, of which 11 were diagnosed with schizophrenia and 3 had some atypical 
depression symptoms.  Kabes study shows there is a positive correlation b/w post treatment 
clinical improvement and biochemical levels using piracetam. 
The mean change from baseline for improvement in behavior or cognitive functions, illustrated 
in Table 2, shows 1.2 for 800mg piracetam TID versus 0.3 for placebo,  29.148 for 800mg (2) 
piracetam TID versus 5.742 placebo, 2.610 for 3200mg piracetam versus 0.482 for placebo and 
finally 0.729 for 2400mg piracetam versus 0.175 for placebo. All studies show statistically 
significant p-values (Table 2) demonstrating efficacy with use of piracetam versus placebo. 
Table 2- Efficacy based on mean change in behavior and cognitive functions 
Study Comparison Mean Change from 
Baseline 
P-value 
Chouinard 
(1983)10 
800mg piracetam TID 1.2 <0.001 
Placebo 0.3 
Dimond (1979)12 800mg (2) piracetam TID 29.148 0.01 
Placebo 5.742 
Noorbala (1999)11 3200mg piracetam 2.610 0.01 
Placebo 0.482 
Kabes (1979)13 2400mg piracetam 0.729 <0.01 
Placebo 0.175 
 
Nguyen, Schizophrenia and Piracetam  8 
 
 For analysis purposes, continuous data was converted into dichotomous data in the 
Chouinard and Kabes study.  Based on the BPRS assessment, the Chouinard study reported 1.2 
of patients on 800mg piracetam TID saw improvement in behavior or cognition function as 
compared to 0.3 on placebo, yielding  a significant p-value <0.001(Table 3).  The corresponding 
NNT was 1, meaning that for every 1 patient treated with 800mg piracetam TID, 1 will see 
improvement as compared to placebo.  The Kabes study reported that 0.79 of patients on 800mg 
(2) piracetam TID saw improvement versus 0.21 on placebo, yielding a p-value <0.01 with a 
NNT of 2, so for every 2 patients treated with 800mg (2) TID piracetam, 1 will see improvement 
as compared to placebo. 
Table 3- Efficacy based on Brief Psychiatric Rating Scale 
Study Comparison Improvement 
from 
baseline 
RBI ABI NNT P-value 
Chouinard10 800mg piracetam TID 1.2 3.0 0.9 1 <0.001 
Placebo 0.3 
Kabes13 2400mg  piracetam 0.79 1.93 0.52 2 <0.01 
Placebo 0.21 
  
 Finally, the Dimond study measured efficacy with the Wing Symptom Rating and the 
Behavior Rating Scale and used ANOVA to calculate F-score. (Table 4)  Patients taking 800mg 
piracetam TID versus placebo yielded an F-score of 5.0718 and a p-value 0.01, statistically 
significant values, meaning improvement was shown in those taking piracetam versus placebo.  
In addition, in the Noorbala study, the PANSS was used to measure efficacy and repeated 
measures of ANOVA with a two-tailed post hoc tukey showed a significant effect of protocols 
on PANSS total scores with a significant p-value of <0.001. 
Nguyen, Schizophrenia and Piracetam  9 
 
Table 4- Efficacy based on ANOVA in behavior and cognitive functions 
Study Comparison Mean F-score P-value 
Dimond12 800mg piracetam TID 29.148 5.0718 0.01 
Placebo 5.742 
 
 With regard to safety or adverse events, it was not addressed any of the studies reviewed. 
DISCUSSION 
 Behavioral and cognitive dysfunction are just some of the very few symptoms 
experienced in schizophrenia, however if left untreated, it can be disabling to the patient.  
Although comparison of the studies, Table 2, showed statistically significant improvement in 
behavioral or cognitive functions with the treatment of piracetam versus a placebo, further 
clinical investigation is required to explain the discrepancy between the doses of piracetam  in 
different individuals as well as what other specific psychotropic agents the patients were taking.   
 Analysis of the Brief Psychiatric Scale (Table 3) continues to support the efficacy of 
piracetam  in that there is a significant improvement of behavioral and cognitive functions with 
p-values of < 0.001 and NNT of 1 and p-values of <0.01 and NNT of 2. This further 
demonstrates that with the addition of piracetam, it is more efficacious than the placebo.  Finally, 
when evaluating efficacy in the Dimond study, ANOVA was used and calculated an F-score of 
5.0718, meaning that of the groups that are different, variance is due to something other than 
chance. In this study, the F-score is also significant. 
 Due to the various discrepancies across all data (the specific dosages of the intervention 
and the timeframe/duration of the study and the patient population), it cannot be used to compare 
treatments across all studies equally. Therefore, analysis and further larger clinical trials 
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regarding optimal dosing is required.  Limitations across studies included various discrepancies 
such as the different dosages of controlled drug, Piracetam; the various duration of timeframe of 
the studies; lack of producibility of whether or not taking the controlled drug was safe or if there 
was any side effects.  Additional limitations include lack of current published studies, small 
sample sizes and discrepancies in the type of patient tested as well as differences in the number 
of patients studied, and numerous methods to evaluate the effects of piracetam on behavioral and 
cognitive functions in patients with schizophrenia.  With all these limitations, there is a 
possibility that it may have affected the statistical power of the study to detect significant 
treatment differences. 
At the present moment, it appears piracetam lacks a future in the United States for its uses as an 
adjuvant therapeutic option for schizophrenia because although piracetam has various off-label 
uses which makes it appealing to practitioners, the FDA has not approved its use in the United 
States.  
 
CONCLUSION 
 Piracetam is a nootropic drug that can improve mental functions in patients with 
schizophrenia, however, based on the analysis of the four trials that were included in this review; 
it is inconclusive if the addition of piracetam will safely and effectively improve behavioral or 
cognitive functions in patients with schizophrenia.  Although there are statistically significant 
outcomes, it is unclear whether the results are clinically significant enough to warrant changes to 
the management of this disease.  Furthermore, future research is warranted since there is lack of 
current published studies, small sample sizes, insufficient data illustrating calculations, and 
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numerous methods to evaluate the effects of piracetam on behavioral and cognitive functions in 
patients with schizophrenia.   
 In some countries, piracetam is available over the counter and is used outside of a 
controlled setting whereas in the United States, it is not FDA approved and therefore not 
available.  Future research should include whether or not patients have comorbid conditions, 
whether or not patients are relapsing, address the optimal dosing schedule for piracetam 
administration and if piracetam is used in conjunction with other psychotropics for it to be 
uniformed throughout, the season that the patients were treated in, and whether or not the 
patient’s improvement is the same in a controlled or uncontrolled environment.  Until such 
research is performed, determination of its true safety profile cannot be validated. 
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